In vitro activity of daptomycin against vancomycin-resistant Enterococci in patients with bacteraemia
Abstract number: R2325
Xanthaki A., Tsiringa A., Skandami-Epitropaki V., Trelogianni X., Dimitriou V., Fotiou P., Toutouza M.
Objectives: The incidence of resistant Gram-positive bacteria in nosocomial infections is increasing. Daptomycin is a newer antimicrobial agent active against Gram-positive pathogens including vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. The aim of this study was to assess the in-vitro activity of Daptomycin by performing susceptibility testing of a set of vancomycin-resistant Enterococci (VRE).
Methods: The collection included 32 VRE isolates (28 E. faecium and 4 E. faecalis) isolated from patients with positive blood cultures between 20052007 in our hospital. Identification to species level was determined with the use of VITEK-II system (BIOMERIEUX-FRANCE). Phenotypically all isolates were of Van A type (vancomycin MIC 256 mg/L, teicoplanin MIC 16 mg/L. They were also susceptible to linezolid and expressed various susceptibility patterns to other antibiotics. Daptomycin MICs were determined by E-test method (AB Biodisk, Solna, Sweden). 4 mg/L was used as a susceptible breakpoint as approved by CLSI.
Results: Daptomycin showed very good activity, with all but one enterococcal isolates being in the susceptible range. Daptomycin MICs for vancomycin-resistant E. faecium: 39.3% (11/28) at 2 mg/L, 35.7% (10/28) at 3 mg/L, 21.4% (6/28) at 4 mg/L and 3.57% (1/28) at 8 mg/L. Daptomycin MICs for vancomycin-resistant E. faecalis: 25% (1/4) at 1 mg/L, 25% (1/4) at 1.5 mg/L, 25% (1/4) at 3 mg/L and 25% (1/4) at 4 mg/L.
Conclusion: Daptomycin was proved to be highly active against VRE isolates from patients with bacteraemia and appears to be a very good therapeutic option in treating serious infections.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|